TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23223921

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty (MAIT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Partial turbinectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 35
Study: 21226886

Group type: EXPERIMENTAL
Intervention: Abstinence-contingent employment
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (independent of drug use)
Number of subjects: 51
Study: 19521351

Group type: EXPERIMENTAL
Intervention: Pramlintide/metreleptin (360 microg/5 mg b.i.d.)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Pramlintide (360 microg b.i.d.)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Metreleptin (5 mg b.i.d.)
Number of subjects: 177
Study: 17845277

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 833
Study: 14984857

Group type: EXPERIMENTAL
Intervention: Droperidol 10 microg.kg(‐1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg.kg(‐1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Droperidol 40 microg.kg(‐1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Droperidol 80 microg.kg(‐1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no droperidol)
Number of subjects: 82
Study: 11491418

Group type: COMPARATOR
Intervention: Combivir
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combivir plus abacavir
Number of subjects: 75
Study: 10067662

Group type: EXPERIMENTAL
Intervention: L-carnitine (0.28 micromole/kg bw/minute)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 35
Study: 7622258

Group type: EXPERIMENTAL
Intervention: Dicloxacillin (0.5 g, 0.75 g, or 1.0 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flucloxacillin (0.75 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dicloxacillin and Flucloxacillin
Number of subjects: 12
Study: 2239935

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 22
Study: 321005

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 61

Group type: COMPARATOR
Intervention: Parenteral penicillin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bacteriological studies
Number of subjects: 61
Study: 31228534

Group type: EXPERIMENTAL
Intervention: Prioritizing extending life
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Prioritizing relief of discomfort
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Unsure of prioritized value
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Older patients prioritizing relief of discomfort
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Patients with better self-perceived health prioritizing relief of discomfort
Number of subjects: 535
Study: 29202549

Group type: EXPERIMENTAL
Intervention: Clonidine (0.5 to 2.0 mg orally)
Number of subjects: 45
Study: 25245427

Group type: EXPERIMENTAL
Intervention: Multilevel modeling approach for analyzing accelerometer data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods for analyzing accelerometer data
Number of subjects: 0
Study: 23612508

Group type: EXPERIMENTAL
Intervention: ADF-HF diet
Number of subjects: 35

Group type: COMPARATOR
Intervention: ADF-LF diet
Number of subjects: 35
Study: 21375545

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 40
Study: 19596415

Group type: EXPERIMENTAL
Intervention: H5N1 inactivated subvirion vaccine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Algorithm-predicted epitopes
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Individual HA peptides identified from the library
Number of subjects: 35
Study: 17006875

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg immediately following surgery and every 24 h for a further three days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 14747125

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleting (LD) arterial line filter
Number of subjects: 192

Group type: COMPARATOR
Intervention: Avecor Affinity or Pall Autovent-6 control filter
Number of subjects: 192
Study: 11268298

Group type: COMPARATOR
Intervention: Hormone-based therapies (progestins, androgens, GnRH analogs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical therapy (hysterectomy with oophorectomy or organ-sparing surgery)
Number of subjects: 0
Study: 9710338

Group type: EXPERIMENTAL
Intervention: Probe-tube microphone measurements of insertion gain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sound field threshold measurements
Number of subjects: 0
Study: 8721471

Group type: EXPERIMENTAL
Intervention: Acupressure bands on the P-6 acupoint
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo bands on the P-6 acupoint
Number of subjects: 60
Study: 2688036

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg three times a day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 4940876

Group type: EXPERIMENTAL
Intervention: Cyclacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 0
Study: 30640504

Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens (experimental condition)
Number of subjects: 411
Study: 28603046

Group type: EXPERIMENTAL
Intervention: Hydroxycamptothecin (HCPT)
Number of subjects: 0
Study: 26960500

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg PO OD) as second-line treatment
Number of subjects: 23
Study: 24187287

Group type: EXPERIMENTAL
Intervention: Arm support (AS) training device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional reach training (CON)
Number of subjects: 0
Study: 22111771

Group type: EXPERIMENTAL
Intervention: Patellofemoral arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total knee arthroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 19487905

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r) 800/100 mg once daily
Number of subjects: 689

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg total daily dose
Number of subjects: 689
Study: 16469156

Group type: EXPERIMENTAL
Intervention: LKFibre diet
Number of subjects: 38
Study: 15349011

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 18 days
Number of subjects: 20
Study: 11421518

Group type: EXPERIMENTAL
Intervention: Progressive resistance muscle strength training
Number of subjects: 19
Study: 9252930

Group type: EXPERIMENTAL
Intervention: Cervex-Brush
Number of subjects: 213

Group type: COMPARATOR
Intervention: Spatula plus Cytobrush (S+C)
Number of subjects: 213
Study: 8501340

Group type: EXPERIMENTAL
Intervention: Clofazimine 50 mg daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 110
Study: 2443619

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 IV bolus daily for five days, then 200 mg/m2 IV bolus every other day for six doses
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 50 mg/m2 IV infusion over four hours followed by IV bolus of 5-FU 600 mg/m2 weekly for 4 weeks and then every 2 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Leucovorin 500 mg/m2 IV infusion with 5-FU 600 mg/m2 IV bolus one hour after Leucovorin every week for 6 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone
Number of subjects: 74

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) and methotrexate (MTX)
Number of subjects: 74
Study: 31734098

Group type: EXPERIMENTAL
Intervention: nalbuphine 0.08 mg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 60
Study: 30481183

Group type: EXPERIMENTAL
Intervention: Psychological advocacy (SPA) sessions (8 sessions with 2 follow-up sessions)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Normal DVA advocacy (control group)
Number of subjects: 263
Study: 28263399

Group type: EXPERIMENTAL
Intervention: Reflective-behavioral gratitude journal
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Reflective gratitude journal
Number of subjects: 192

Group type: COMPARATOR
Intervention: Active control journal
Number of subjects: 192
Study: 25150557

Group type: EXPERIMENTAL
Intervention: Barthel Index assessment
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Professional judgment of nursing care needs
Number of subjects: 878
Study: 23290580

Group type: EXPERIMENTAL
Intervention: Full model (considering both misclassification and missing data)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative models (considering only misclassification or only missing data)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naïve model (ignoring both sources of bias)
Number of subjects: 0
Study: 21885490

Group type: EXPERIMENTAL
Intervention: VLD cyclobenzaprine (CBP) 1-4 mg at bedtime
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19546753

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 300

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 300
Study: 16936208

Group type: EXPERIMENTAL
Intervention: T-cell proliferative assay
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Immunoblot assay
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Autoantibody assay
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combined cellular assays and autoantibody measurements
Number of subjects: 62
Study: 12921194

Group type: EXPERIMENTAL
Intervention: Older adults (aged 55 and over)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Middle-aged adults (aged 40 to 54)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Younger adults (aged 18-39)
Number of subjects: 1204
Study: 10720126

Group type: EXPERIMENTAL
Intervention: Third intensification block at week 35
Number of subjects: 1781

Group type: COMPARATOR
Intervention: No third intensification block
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Third intensification block
Number of subjects: 1781

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1781
Study: 9360512

Group type: EXPERIMENTAL
Intervention: [norleucine27]GHRH (1-29)-NH2 at a dose of 10 micrograms/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: [norleucine27]GHRH (1-29)-NH2
Number of subjects: 19
Study: 8255636

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate (SCG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 15
Study: 3834842

Group type: EXPERIMENTAL
Intervention: Chloroquine (weekly malaria chemoprophylaxis)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control (age-matched children without chloroquine)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Children with malaria parasitaemia
Number of subjects: 198

Group type: COMPARATOR
Intervention: Children without malaria parasitaemia
Number of subjects: 198
Study: 30357256

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (n = 477)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Intermediate tidal volume ventilation (n = 484)
Number of subjects: 961
Study: 26762727

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS <7%
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS <7% with moderate/severe aortic regurgitation (AR) at discharge
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation in patients with STS >7% with moderate/severe aortic regurgitation (AR) at discharge
Number of subjects: 996

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation in both STS <7% and STS >7% groups
Number of subjects: 996
Study: 25170226

Group type: EXPERIMENTAL
Intervention: 160 mg/d PI-88
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 250 mg/d PI-88
Number of subjects: 143

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 143
Study: 22576717

Group type: EXPERIMENTAL
Intervention: Mentored learning (lecture and coaching)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self-directed learning (no mentoring)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mentored learning (4 months later)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self-directed learning (4 months later)
Number of subjects: 16
Study: 20719465

Group type: EXPERIMENTAL
Intervention: Bivalirudin (0.75 mg/kg intravenous bolus and intraprocedural infusion at 1.75 mg/kg/h)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Unfractionated heparin (100 UI/kg)
Number of subjects: 220
Study: 18308431

Group type: EXPERIMENTAL
Intervention: Lower-GI diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Higher-GI diet
Number of subjects: 32
Study: 15977006

Group type: EXPERIMENTAL
Intervention: Intramedullary fixation with a titanium pin (surgical intervention)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rucksack bandage (nonoperative treatment)
Number of subjects: 27
Study: 12452023

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin regimen (PC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ifosfamide, etoposide, and carboplatin regimen (IEC)
Number of subjects: 68
Study: 10360907

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ovulatory controls
Number of subjects: 35
Study: 7497366

Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Gamma Nail (GN)
Number of subjects: 101
Study: 1779009

Group type: EXPERIMENTAL
Intervention: Estimates made by nurses
Number of subjects: 57

Group type: COMPARATOR
Intervention: Estimates made by physicians
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Standardized burn forms
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methods used for estimating burn size
Number of subjects: 57
Study: 7035637

Group type: EXPERIMENTAL
Intervention: PRP-P
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 71

Group type: COMPARATOR
Intervention: DTP
Number of subjects: 71
Study: 30457029

Group type: COMPARATOR
Intervention: Conventional ultrasound device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pocket-sized ultrasound
Number of subjects: 20
Study: 28544150

Group type: EXPERIMENTAL
Intervention: D‐ADM (single application)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: D‐ADM (all applications)
Number of subjects: 168

Group type: COMPARATOR
Intervention: GJ‐ADM
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: GJ‐ADM (single application)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: D‐ADM
Number of subjects: 168
Study: 25985038

Group type: EXPERIMENTAL
Intervention: 20% lignocaine HCl and 0.1% epinephrine HCl with iontophoretic current of 120 μA for 90s
Number of subjects: 13

Group type: COMPARATOR
Intervention: Epinephrine solution (control)
Number of subjects: 13
Study: 24039234

Group type: EXPERIMENTAL
Intervention: BPS management (antibiotic indication with a BPS ≥ 4 points)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine management (antibiotic indication based on institutional guidelines)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: BPS management
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 120
Study: 22461445

Group type: EXPERIMENTAL
Intervention: Eccentric training program (3 sessions/week; 3-5 sets of 10 repetitions with loads between 40-50% of maximal isometric voluntary contraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acute eccentric exercise (first bout)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acute eccentric exercise (second bout after training)
Number of subjects: 20
Study: 19407468

Group type: EXPERIMENTAL
Intervention: Wipe A
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Wipe B
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cloth and water (control)
Number of subjects: 130
Study: 17304686

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 24
Study: 16094064

Group type: EXPERIMENTAL
Intervention: Combination therapy (desmopressin plus oxybutynin)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Desmopressin alone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Imipramine alone
Number of subjects: 145
Study: 12526285

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) once daily for 24 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Finasteride (5 mg) once daily for 24 weeks
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg) at 4 weeks
Number of subjects: 205

Group type: COMPARATOR
Intervention: Finasteride (5 mg) at 4 weeks
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Adverse events for Tamsulosin
Number of subjects: 205

Group type: COMPARATOR
Intervention: Adverse events for Finasteride
Number of subjects: 205
Study: 10609436

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 7718078

Group type: EXPERIMENTAL
Intervention: Video sign warning plus role model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video sign warning plus role model with voice warning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video sign warning alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video warning with delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video role model and voice warning
Number of subjects: 0
Study: 2248062

Group type: EXPERIMENTAL
Intervention: Moclobemide (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide (200 mg, 3 times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomipramine (25 mg, twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (0.6 g/l)
Number of subjects: 0
Study: 7410783

Group type: EXPERIMENTAL
Intervention: Geriatric day care services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homemaker services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined geriatric day care and homemaker services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased use of experimental services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Factors affecting outcomes
Number of subjects: 0
Study: 31490252

Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate (FC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cryoprecipitate
Number of subjects: 60
Study: 30106328

Group type: EXPERIMENTAL
Intervention: Music- and verbally cued motor imagery (MVMI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music-cued motor imagery (MMI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-cued motor imagery (MI)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cued motor imagery (MVMI, MMI)
Number of subjects: 60
Study: 28645259

Group type: EXPERIMENTAL
Intervention: Yoga programme (n=25)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list control (n=27)
Number of subjects: 52
Study: 26151607

Group type: EXPERIMENTAL
Intervention: Everolimus + Reduced Tacrolimus (EVR + Reduced TAC)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard exposure Tacrolimus (TAC Control)
Number of subjects: 370
Study: 23183751

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1200 IU), folic acid (0.5 mg), vitamin B12 (0.5 mg), vitamin B6 (50 mg), and calcium carbonate (456 mg) (group A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1200 IU) and calcium carbonate (group B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: B vitamins (group A)
Number of subjects: 93
Study: 21721475

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (standard multivitamin formula with phytonutrients); details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details not available.
Number of subjects: 0
Study: 19781415

Group type: EXPERIMENTAL
Intervention: Aortic valve calcification (AVC)
Number of subjects: 357
Study: 17922899

Group type: EXPERIMENTAL
Intervention: 1 mg Nicotinell lozenge
Number of subjects: 900
Study: 12898201

Group type: EXPERIMENTAL
Intervention: FLT PET
Number of subjects: 16

Group type: COMPARATOR
Intervention: FDG PET
Number of subjects: 16
Study: 11023459

Group type: EXPERIMENTAL
Intervention: HIV-1 envelope vaccines
Number of subjects: 0
Study: 9182469

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 1587067

Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 mg ephedrine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3886400

Group type: EXPERIMENTAL
Intervention: Urapidil 30 mg b.i.d.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Clonidine 0.075-0.15 mg b.i.d.
Number of subjects: 11
Study: 29468978

Group type: EXPERIMENTAL
Intervention: Echium amoenum compound syrup (EACS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Citalopram tablet
Number of subjects: 50
Study: 29479950

Group type: EXPERIMENTAL
Intervention: Adhesive strip applied to the eyelids post-rhinoplasty
Number of subjects: 0
Study: 27175680

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.25 μg/kg/h diluted to 100 mL in 0.9% saline
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl 20 μg/kg diluted to 100 mL in 0.9% saline
Number of subjects: 40